3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Small Cell Lung Carcinoma
6
Lung Neoplasms
2
Neoplasms
1
Leiomyosarcoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
16
Bevacizumab
12
Carboplatin
10
Nivolumab
8
Pemetrexed
7
Temozolomide
6
Standard of Care
6
Exercise
6
Cetuximab
6
durvalumab
5
atezolizumab
5
Prednisone
5
Cyclophosphamide
5
abemaciclib
4
Paclitaxel
4
Doxorubicin
4
Dexamethasone
4
Cisplatin
4
Blood Specimen Collection
4
temsirolimus
3
enzalutamide
3
dostarlimab
3
daratumumab
3
cabozantinib
3
Rituximab
3
Oxaliplatin
3
Metformin
3
Leucovorin
3
Lenalidomide
3
Ipilimumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
PM 01183
×
30 days
×
Clear all
NCT06088290
2026-05-15
SaLuDo
PharmaMar
Phase 3
Active not recruiting
455 enrolled